fda category 2 bulk drug substances bpc-157 compounding list considers adding a dozen peptides to its This just in: The FDA
This just in: The FDA is proposing to move 14 commonly used peptides from Category 2 to Category 1 on the compounding review list If finalized, this shift could significantly change FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of FDA Set to Review Peptide Access for Compounding Pharmacies Drug Topics Peptides in 2026, What the FDA Review Means Olympia Pharmaceuticals FDA panel backs compounded BPC 157, KPV peptides in win for RFK Jr. STAT
Pay in 4 interest-free payments of $6.64 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6




